Advanced Accelerator Applications
20 Rue Diesel
Saint Genis Pouilly
01630
France
Tel: 33-0-4-50-99-30-70
Fax: 33-0-4-50-99-30-71
Website: http://www.adacap.com/
78 articles with Advanced Accelerator Applications
-
Days after Novartis axed one-fifth of its research programs, the Swiss pharma giant said it intends to seek regulatory approval for 60 new treatments between 2019 and 2021.
-
Shares of Indiana-based Endocyte have shot up more than 50 percent in pre-market trading after Swiss pharma giant Novartis announced it was acquiring the company for $2.1 billion in cash. The deal will allow the company to expand its radiopharmaceuticals business.
-
Pharma and biotech companies across the globe continued to expand and reshape their leadership teams with new hires this past week. BioSpace collected several announced leadership appointments, which includes new chief executive officers, new members to boards of directors and more.
-
Advanced Accelerator Applications Signs Exclusive License Agreement With Cancer Targeted Technology to Develop CTT1057, an F-18 Labeled PSMA Ligand for Diagnostic Applications in Prostate Cancer
2/12/2018
The terms of the agreement include an upfront licensing fee, as well as certain milestone and royalty payments.
-
Novartis Completes Subsequent Offering Period of the Tender Offer for Advanced Accelerator Applications S.A.
2/2/2018
The subsequent offering period for the Offer, which commenced on January 22, 2018, expired as scheduled at 12:00 midnight, New York City Time, on January 31, 2018.
-
The drug is the first available FDA-approved Peptide Receptor Radionuclide Therapy.
-
Novartis Completes Tender Offer for Advanced Accelerator Applications S.A. and Announces Commencement of Subsequent Offering Period
1/22/2018
The deal expands Novartis Oncology neuroendocrine tumor treatment portfolio and adds radiopharmaceutical technology platform.
-
From 1997 through 2013, there was an average of 27 novel drugs approved in the U.S. per year.
-
Advanced Accelerator Applications Announces Commencement of Novartis Tender Offer
12/7/2017
The Offer will expire at 12:00 midnight, New York City time, on January 19, 2018, unless extended (the latest time and date at which the Offer will expire, the “Expiration Date”).
-
Advanced Accelerator Applications Board of Directors Recommends $3.9B All Cash Tender Offer by Novartis
12/6/2017
The transaction is subject to customary transactional regulatory approvals.
-
Advanced Accelerator Applications Reports 39% Sales Growth for Third Quarter 2017
11/17/2017
Sales for the third quarter of 2017 increased 39% compared to the third quarter of 2016
-
Advanced Accelerator Applications Announces European Approval Of Lutetium (177Lu) Oxodotreotide (Lutathera) For Gastroenteropancreatic Neuroendocrine (GEP-NET) Tumors
9/29/2017
-
Advanced Accelerator Applications And FUJIFILM RI Pharma Announce First Patient In Bridging Study In Japan For Lutetium Lu 177 Dotatate* (Lutathera)
9/6/2017
-
Advanced Accelerator Applications Reports 32% Sales Growth For Second Quarter 2017
8/31/2017
-
Advanced Accelerator Applications Announces New Prescription Drug User Fee Act (PDUFA) Date Of January 26, 2018, For Lutetium Lu 177 Dotatate (Lutathera)
8/28/2017
-
Advanced Accelerator Applications Completes Resubmission Of NDA For Lutetium Lu 177 Dotatate (Lutathera) To FDA
7/27/2017
-
EU Regulators Give Nod to Advanced Accelerator Applications ' Med to Treat the Cancer That Killed Steve Jobs
7/21/2017
-
Advanced Accelerator Applications Reports 21% Sales Growth For First Quarter 2017
5/31/2017
-
Advanced Accelerator Applications And Blue Earth Diagnostics Announce European Manufacturing And Distribution Agreements For Axumin (Fluciclovine (18F)) For PET Imaging Of Recurrent Prostate Cancer
5/30/2017
-
Advanced Accelerator Applications Appoints Christine Mikail To Board Of Directors
5/25/2017